Targeted Therapy Treatment Innovations in AML - Episode 3

Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.